Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock

Core Viewpoint - Altimmune, Inc. has entered into a securities purchase agreement for the sale of 17,045,454 shares of common stock, expected to generate approximately $75 million in gross proceeds, to fund its Phase 3 trial for pemvidutide and for general corporate purposes [1][2]. Group 1: Offering Details - The offering involves 17,045,454 shares of common stock or pre-funded warrants, with gross proceeds anticipated to be around $75 million before expenses [1]. - The offering is expected to close on or about January 29, 2026, pending customary closing conditions [1]. - Titan Partners is acting as the sole placement agent for this offering [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to prepare for the upcoming Phase 3 trial in metabolic dysfunction-associated steatohepatitis (MASH), along with working capital and general corporate purposes [2]. - Pemvidutide is a dual agonist targeting glucagon and GLP-1 receptors, showing potential as a differentiated therapy for MASH, supported by recent Phase 2b data and Breakthrough Therapy Designation from the U.S. FDA [2]. Group 3: Company Overview - Altimmune is a late clinical-stage biopharmaceutical company focused on therapies for serious liver diseases, with pemvidutide as its lead candidate [6]. - The company aims to deliver significant patient impact and long-term shareholder value through its innovative therapies [2].